Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  International Journal of Radiation Oncology, Biology, Physics

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijrobp.2009.05.031PMID 19836157
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

  2010cited by this paper
• Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

  2008cited by this paper
• Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

  2007cited by this paper
• Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

  2007cited by this paper
• Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

  2006cited by this paper
• Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)

  2006cited by this paper
• Is protracted low-dose temozolomide feasible in glioma patients?

  2006cited by this paper
• Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

  2006cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Temozolomide Combined with Irradiation as Postoperative Treatment of Primary Glioblastoma Multiforme

  2005cited by this paper
• Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• A phase II study of temozolomide administered 21 out of 28 days for the treatment of patients with recurrent anaplastic (oligo)astrocytoma: An interim analysis of toxicity

  2005cited by this paper
• MGMT: its role in cancer aetiology and cancer therapeutics

  2004cited by this paper
• Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

  2003cited by this paper
• Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?

  2003cited by this paper
• Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.

  2003cited by this paper
• Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-kappaB activation in HeLa cells occur via a mechanism involving p38 MAP kinase.

  2001cited by this paper
• Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.

  2001cited by this paper
• Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

  2000cited by this paper
• A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

  2000cited by this paper
• Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors.

  1994cited by this paper
• Response criteria for phase II studies of supratentorial malignant glioma.

  1990cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Pneumocystis jirovecii pneumonia prophylaxis in patients with glioma receiving concurrent chemoradiation: a systematic review and meta-analysis

  2025cites this paper
• Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial

  2023cites this paper
• Immunohistochemical expression of MGMT in gliomas and its role in ascertaining patient survival

  2021cites this paper
• Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes

  2021cites this paper
• The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme

  2020cites this paper
• Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults

  2020cites this paper
• Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide

  2020cites this paper
• The Effects of O6-methyl Guanine DNA-methyl Transferase Promotor Methylation and CpG1, CpG2, CpG3 and CpG4 Methylation on Treatment Response and their Prognostic Significance in Patients with Glioblastoma

  2020cites this paper
• Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

  2020cites this paper
• MORPHOLOGIC AND MOLECULAR FEATURES OF PRIMARY GLIOBLASTOMA IN PATIENTS SURVIVING MORE THAN 3 YEARS

  2019cites this paper
• МОРФОЛОГИЧЕСКИЕ И МОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ ПЕРВИЧНЫХ ГЛИОБЛАСТОМ У ПАЦИЕНТОВ С НЕОБЫЧНО ВЫСОКОЙ ПРОДОЛЖИТЕЛЬНОСТЬЮ ЖИЗНИ

  2019cites this paper
• Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.

  2018cites this paper
• Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)

  2018cites this paper
• Treatment of glioblastoma in adults

  2018cites this paper
• In vitro antiglioma action of indomethacin is mediated via AMP-activated protein kinase/mTOR complex 1 signalling pathway.

  2017cites this paper
• Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma

  2017cites this paper
• Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma

  2017cites this paper
• Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials

  2016cites this paper
• The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma.

  2016cites this paper
• Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide

  2016cites this paper
• Therapie des Gliommikromilieus

  2015cites this paper
• Severe Cholestatic Hepatitis due to Temozolomide: An Adverse Drug Effect to Keep in Mind. Case Report and Review of Literature

  2015cites this paper
• The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis

  2015cites this paper
• Epigenetics Territory and Cancer

  2015cites this paper
• Avaliação da participação de grânulos de estresse na resposta a agentes antineoplásicos em linhagens celulares de tumores cerebrais

  2015cites this paper
• [Treatment of the glioma microenvironment].

  2015cites this paper
• Judging Quality and Coordination in Biomarker Diagnostic Development

  2015cites this paper
• Predictive Role of O6-Methylguanine DNA Methyltransferase Status for the Treatment of Brain Tumors

  2015cites this paper
• MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma.

  2015cites this paper
• Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review)

  2015cites this paper
• Nanoparticle based strategies for the treatment of Glioblastoma

  2014cites this paper
• The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in Elderly Glioblastoma Patients: A Meta-Analysis

  2014cites this paper
• Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.

  2014cites this paper
• Phase II rial of 7 days on / 7 days off temozolmide for recurrent high-grade glioma

  2014cites this paper
• Prognostic Impact of MGMT Promoter Methylation in Glioblastoma - A Systematic Review

  2014influential citation
• Inadvertent High-dose Therapy With Temozolomide in a Child With Recurrent Pontine Glioma Followed by a Rapid Clinical Response But Deteriorated After Substitution With Low-dose Therapy

  2014cites this paper
• Microenvironmental Clues for Glioma Immunotherapy

  2014cites this paper
• Prognostischer Wert der 18Fluor- Ethyl-Tyrosin-Positronenemissionstomographie im Rahmen des Therapiemonitorings bei Glioblastoma multiforme

  2014cites this paper
• Biomarkers for Brain Gliomas

  2014cites this paper
• Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?

  2013cites this paper
• mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy

  2013cites this paper
• Restoration of Sensitivity in Chemo — Resistant Glioma Cells by Cold Atmospheric Plasma

  2013cites this paper
• Personalized treatment strategies in glioblastoma: MGMT promoter methylation status

  2013cites this paper
• Diagnosis and prognosis of brain tumors in clinical trials

  2013cites this paper
• Personalized treatment strategies in glioblastoma: MGMT promoter methylation status

  2013cites this paper
• Oncology scan--high-grade gliomas.

  2013cites this paper
• Oncology ScandHigh-Grade Gliomas

  2013cites this paper
• Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system.

  2012cites this paper
• Temozolomide and other potential agents for the treatment of glioblastoma multiforme.

  2012cites this paper
• Temozolomide Other Potential Agents for the Treatment of Glioblastoma

  2012cites this paper
• MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry

  2012cites this paper
• Strength of skeletal muscle and self-reported physical performance in Austrian glioblastoma-patients

  2012cites this paper
• MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

  2012cites this paper
• Decision making and management of gliomas: practical considerations.

  2012cites this paper
• Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma

  2012influential citation
• Factores pronósticos en astrocitomas anaplásicos

  2011cites this paper
• Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM

  2011cites this paper
• Immature and absolute platelet count changes and thrombocytopenia in malignant glioma

  2011cites this paper
• Diagnostic markers for glioblastoma.

  2011cites this paper
• Review Diagnostic markers for glioblastoma

  2011cites this paper
• Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?

  2011cites this paper
• The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations

  2011cites this paper
• The mitochondrial translocator protein in human gliomas.

  2010cites this paper
• Prognostic markers in gliomas.

  2010cites this paper
• Temozolomide: Expanding its role in brain cancer.

  2010cites this paper
• MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

  2010cites this paper